||Alnylam Pharmaceuticals, Inc.
||United States District Court for the District of Massachusetts
||The Hon. Nathaniel M. Gorton
||Between September 20, 2017 and September 12, 2018
On September 26, 2018, the initial complaint in this securities class action was filed against Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”), and certain of Alnylam’s directors and officers, asserting violations of sections 10(b) and 20(a) of the Securities Exchange Act.
The complaint alleged that throughout the class period, the defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, the complaint alleged that the defendants made false and/or misleading statements and/or failed to disclose that: (i) Alnylam overstated the efficacy and safety of its Onpattro (patisiran) lipid complex injection; and (ii) as a result, Alnylam’s public statements were materially false and misleading at all relevant times.
This securities class action lawsuit was brought on behalf of all persons or entities who purchased or otherwise acquired Alnylam securities between September 20, 2017 and September 12, 2018, inclusive.
Current Status of Case:
On March 23, 2020, the Court granted the defendants' motion to dismiss the lead plaintiff’s amended complaint. On June 1, 2020, the lead plaintiff filed a motion for leave to file a second amended complaint. The defendants filed an opposition to this motion on June 15, 2020. The motion for leave to file a second amended complaint is now fully briefed before the Court pending its decision. This action is still ongoing.
If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.
Kessler Topaz Meltzer & Check, LLP
James Maro, Esq. or Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087 1-844-887-9500 (toll free) or 1-610-667-7706
Or by e-mail at firstname.lastname@example.org